Twelve Prominent Professionals Elected to MedTech's 2011-2012 Board of Directors

Thursday, October 27, 2011

SYRACUSE, NY- October, 27, 2011- MedTech, the hub of Upstate New York’s bioscience and medical technology industry, announces the election of twelve well-known, community and industry leaders to its 2011-2012 Board of Directors. MedTech appreciates the distinguished efforts of its 2010-2011 Board of Directors and looks forward to bringing the organization to next stage together with its new directors.

For a complete list of the MedTech Board of Directors, visithttp://www.medtech.org/about/board.aspx.

 

Three Albany-area executives were named to the board:

John Boger, a partner with the intellectual property law firm Heslin Rothenberg Farley & Mesiti, was elected as a director-at-large and will co-chair the MedTech Issues, Events & Services committee. He graduated cum laude from Syracuse University College of Law, and also received a bachelor’s degree in biomedical engineering from Syracuse University and a master’s degree in biomedical engineering from the University of Utah. Prior to joining Heslin Rothenberg Farley & Mesiti, Boger was senior counsel to Capital District Physicians' Health Plan, Inc. Before attending law school, he worked for eight years at DePuy, Inc. as a product development engineer and product manager specializing in orthopedic implant design. He also worked for DePuy-DuPont Orthopedics, Inc. as the venture project manager, focusing on the development of advanced implantable biomaterials. Boger is admitted to practice law in New York state and is registered to practice before the United States Patent and Trademark Office.

Boger’s desire to serve on the MedTech Board of Directors is based on his interest in facilitating communication and business relationships throughout the Upstate New York medical technology community.

“I look forward to contributing to MedTech’s ongoing mission of offering high quality educational and development programs to its members,” said Boger in his vision statement.

Tracy MacNeal, vice president of business development at Praxis Technology, was elected as a director. At Praxis, MacNeal is currently responsible for the expansion of the firm’s portfolio through the development of strategic licensing and manufacturing relationships, as well as stewardship of Praxisfinances and corporate strategy. Her background includes new product launches in pharmaceuticals with Merck and consulting for several startups in cosmetics and sterile injectables.

MacNeal hopes that MedTech will become a catalyst for clarity in the healthcare community.  MacNeal looks forward to helping enable MedTech’s membership to more effectively separate the essential from the nonessential in this rapid changing regulatory, reimbursement, and technology landscape, as she expressed In her vision statement.

Harold Meckler,vice president of science & technology at AMRI, was elected as a director.  Meckler is responsible for internal research projects, generic drug research, scientific information systems, sample collections and laboratory based facilities at AMRI. Previous to AMRI, Meckler was employed by Telor Ophthalmic Pharmaceuticals in Wilmington, Mass. where he established the organic chemistry department and the cGMP kilo lab facility. He also worked in the chemical development departments at the Ciba Geigy Pharmaceutical Division (now Novartis Corporation) in Summit, N.J., and also in the Chemical Development group at the Sterling Winthrop Research Institute in Rensselaer, N.Y. Meckler earned his doctorate in organic chemistry from the State University of New York at Buffalo and his bachelor’s degree in chemistry from the University of Maryland. He is a member of the Advisory Board of Chemical and Engineering News and the Editorial Advisory Board of Organic Process Research and Development, as well as a member of the board of directors of Pittsburgh-based Fluorous Technologies, Inc. He is a founding member of BioConnex and serves on its steering committee.

Meckler always believes that the biotechnology, pharmaceutical and medical device industries will be one of the growth engines for the economic development of New York state.

“There is much potential for the industry to expand in conjunction with the growth in the nanotech, clean tech and IT industries,” said Meckler in his vision statement, “This, in turn, presents opportunities for MedTech to lead by example and become a vehicle for industrial, academic and public sector interests to collaborate for the advancement of the region.”

 

One Utica-area executive has been named to the board:

Dan Jonas,a founding member of MedTech and Board member since 2004, has been elected as a director. Jonas joined ConMed Corporation as general counsel in August 1998 and became the vice president of legal affairs in March 1999. In September 1999 through July 2005, Jonas assumed responsibility for some of ConMed’s Regulatory Affairs and Quality Assurance departments. In March 2003, he also became responsible for the administration of ConMed’s ethics policy. Before serving as chair of the MedTech Board of Directors, Jonas was secretary of the Board and also served as co- chair of the MedTech Issues, Events & Services committee.

According to his vision statement, Jonas looks forward to continuing his work with other directors to identify synergies and enhance collaboration between bioscience companies. As MedTech expands in membership and program offerings, Jonas sees the association playing an increasing role as a voice for the industry’s common challenges and interests with Federal and State government representatives.

 

Four Syracuse-area executives were named to the board:

David J. Eilers,vice president of business development at Blue Highway, was elected as a director and will co-chair the MedTech Issues, Events & Services committee. Eilers has been an enterprise leader in both the consumer and healthcare industries for 30 years. A graduate Syracuse University, Eilers began his career in marketing management; leading key accounts at Eric Mower and Associates, Cowley Associates, TenaZ Import/Export Corporation and Syracuse China Corporation. In 1998, Eilers entered the healthcare industry as the vice president of sales and marketing at B.G. Sulzle, Inc. Over the course of 15 years, he pioneered new products, opened new international markets and developed new business models for the healthcare industry through his work with InterV Medical Group/Roundtable Healthcare Partners and NextTech Consulting. In 2008, Eilers applied his interest in open innovation business models to the co-founding of Blue Highway (formerly a subsidiary of Welch Allyn). He has co-developed medical devices at a number of clinical centers including Brigham & Women’s Hospital, Mayo Clinic and Cleveland Clinic.

According to his vision statement, Eilers desires to be a catalyst for enhanced innovation activity, which entails reaching out to the start-up community and providing avenues for development and commercialization, and in addition, being a liaison between emerging enterprises and well-established corporations that are open to outside collaborators. If this can be put into effect, he believes, MedTech will thrive and the healthcare sector of the economy will flourish in New York state.

Holly Hoehner,partner at Hiscock & Barclay, LLP in the Business Services group, was elected as a director-at-large and has served as chair of the MedTech Governance & Nominating committee since 2009. In her role at Hiscock & Barclay, Hoehner focuses on corporate and commercial contracts and transactions, especially relating to intellectual property licensing and health care. She also concentrates on ethics and corporate compliance, including fraud & abuse counseling relative to the marketing of drugs and devices. Prior to joining the firm in 2005, she served as assistant general counsel at Taro Pharmaceuticals, a publicly traded pharmaceutical manufacturer, where she designed, developed and implemented a worldwide ethics and corporate compliance program and served as chair of Taro's compliance committee. Hoehner holds a bachelor’s degree from Cornell University and a doctorate of law from Columbia Law School.

In her vision statement, Hoehner presents her support for MedTech’s efforts to bring together the medical technology companies in Upstate New York and the academic and service organizations that support them.

According to Hoehner, “We need a strong platform like MedTech to advocate our mutual interests, promote our region, and provide opportunities for education and collaboration. I hope to lend my perspective and assistance to help advance MedTech’s mission.”

Bruce Kirk,director of corporate innovation effectiveness at Corning, Inc., was elected as a director. At Corning, Kirk is responsible for the innovation process development and deployment, employee education and training, global benchmarking, next generation process development and the implementation of the Innovation Black Belt role throughout Corning. He is the corporate process owner of Corning’s Five Stage Innovation Process and the Roadmapping process. His career experience has spanned several Corning divisions since joining the company in 1976, including Medical Products, Science Products, Human Resources, Photonic Technologies, and Science and Technology. He holds a bachelor’s degree in business finance from Susquehanna University.

Kirk wants to see New York State become a place where biomedical companies and individuals desire to locate and prosper through the efforts of MedTech, he said in his vision statement.

Amy Ryan,president of InfiMed, was elected as a director and has served as treasurer of the board and chair of the MedTech Finance committee since 2008.  Ryan has been with InfiMed for 20 years. Prior to her appointment as president, Ryan honed leadership experience as Executive Vice President of the company. With expertise in operations development, engineering, marketing and P&L management, Ryan looks to strengthen InfiMed’s trusted commitment to high quality products, global service and innovative solutions to challenges. As a MedTech director, Ryan’smission is to continue to enhance MedTech’s support for local companies who are bringing innovation to a globalizing medical technologies field.

Ryan seeks to help MedTech attract, enhance and retain talent and businesses in bioscience and medical technology fields through collaboration, education and a sense of community.

 

Two Rochester-area executives were named to the board:

Holly Hillberg,vice president of research and development at Ortho Clinical Diagnostics, was elected as a director. Hillberg is responsible at Ortho Clinical Diagnostics for the pipeline delivery process, driving new growth opportunities and successful commercialization of products to the marketplace. In this role, she identifies and develops diagnostic products and programs that enable people to be healthier, feel better and live longer. She also serves as an executive member of the Ortho Clinical Diagnostics Board. Prior to joining Ortho Clinical Diagnostics in 2011, Hillberg served as the vice president and chief technology officer for Carestream Health and contributed 23-years in R&D, marketing, operations, commercialization and business management at Eastman Kodak Company. Hillberg is an active member of numerous boards, including the Michigan Technological University College of Engineering Industrial Advisory Board, the Rochester Institute of Technology’s Women in Engineering Board, and the Rochester Engineering Society. Holly holds a bachelor’s degree in chemical engineering from Michigan Technological University and bachelor’s and master’s degrees in electrical engineering from Rochester Institute of Technology. Additionally, she is a graduate of the Northwestern University’s Executive Development Program from the Kellogg Graduate School of Management and the Manufacturing Executive Program at the University of Michigan.

As part of the MedTech board, Hillberg describes her role as helping to promote the growth of the Upstate region and to support new economic and intellectual growth with regionally available assets in the biosciences and medical community.

Scott Steele,director of research alliances at University of Rochester, was elected as a director-at-large.  Steele fosters strategic research partnerships between the University of Rochester and industry, government agencies, and other academic institutions. He is actively involved with the University of Rochester Clinical and Translational Science Institute, serving as the director of the Public-Private Partnerships Key Function. Additionally, he holds an adjunct appointment in the Department of Community and Preventive Medicine in the School of Medicine and Dentistry. Prior to joining the University of Rochester, Steele served in the White House Office of Science and Technology Policy, initially as a policy analyst and later as the executive director of the President’s Council of Advisors on Science and Technology. Steele received his bachelor’s degree with honors in biology from Union College in Schenectady, N.Y. Following this, he performed research at the General Electric Center for Research and Development and was a fellow at the National Institutes of Health in Bethesda, Md. Steele completed his master’s degree and doctorate in molecular biology at Princeton University.

“Building on my role at a research university, I wish to enhance a key function for MedTech in fostering industry-university-government alliances in biomedical technology research, development and educational initiatives.” Steele said in his vision statement.

 

Two Buffalo-area executives have been named to the board:

Martin Berardi, corporate vice president at Moog, Inc. and president of Moog Medical Devices Group, was elected as a director. Berardi has worked in all of Moog's groups, spending the first half of his career in the Aerospace areas: Space Systems, Missile Systems, and Aircraft, then transitioning to the Industrial Group in the early 1990s. Prior to becoming a Corporate Vice President, Berardi was General Manager at the Moog facility located in Stuttgart, Germany for three years. He is currently responsible for the newest operating segment of Moog in the Medical Devices Market. Berardi earned his bachelor’s from Canisius College and his M.B.A. in finance from St. Bonaventure University. He serves as Chairman on the Board of Advisors for the Wehle School of Business at Canisius College and the Canisius College Board of Regents. He is on the Board of Advisors for UB/CAT Program through the Center of Excellence, and is Vice Chair, Buffalo Schools Initiative for 43x79 Leadership and is a member of the Board of Advisors for Conax Technologies.

Berardi seeks to bring MedTech a comprehensive understanding of the FDA paradigm change, in order to help various size companies navigate through the 510(k) or Premarket Approval process.

William (Bill) Maggio,president and CEO of IMMCO Diagnostics, Inc., was elected as a director. Maggio has led IMMCO Diagnostics to be a global manufacturer of autoimmune and esoteric diagnostics. Prior to joining IMMCO, Maggio held senior level Business Development and operational positions at Boehringer Mannheim, Roche, and Bureau VERITAS. He has extensive business experience in Europe and Asia having and currently serves on a number of not for profit boards, including the Canisius College Board of Trustees, the University at Buffalo center for Advanced Biomedical and Bioengineering Technology Board of Advisors, and the West Side Rowing Club Board of Directors.

In his vision statement, Bill sees the vitality and scope of the Upstate New York Bio/Med industry as under-recognized and a potential engine for regional growth if nurtured properly.

“MedTech can play a significant role in this regard,” he said. “I plan to support these initiatives, increasing visibility for the organization and strengthening the MedTech network through industry, political and regional relationships developed throughout my career.” Maggio intends to work eagerly on behalf of MedTech to broaden the global impacts of the Upstate New York health care industry.

 

ABOUT MEDTECH

MedTech is an active association of pharmaceutical, biotech, and medical technology companies, their suppliers and service providers, and research universities. We boost the growth and prosperity of our members by connecting them for collaboration, offering educational programs, sharing news and information, and advocating for the industry with government and leaders. Our mission is to develop the relationships, tools and programs that enable Upstate New York companies to bring tomorrow’s medical solutions to the healthcare marketplace. For more information, visithttp://www.medtech.org.    

View All News »